2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON

Felip, E., Shu, C. A., Aguilar, A., Tang, K.-J., García Campelo, M. R., Lee, K.-Y., Delmonte, A., Sabari, J., Girard, N., Mansfield, A. S., Park, K., Zhou, C., Xia, K., Bhattacharya, A., Wade, M., Baig, M., Agrawal, T., Mahadevia, P., Knoblauch, R. E., & Sanborn, R. E. (2024). 2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON. ESMO Open, 9, 102581. https://doi.org/10.1016/j.esmoop.2024.102581
Authors:
Enriqueta Felip
Catherine A. Shu
Andrés Aguilar
K-J. Tang
M.R. García Campelo
KY Lee
Angelo Delmonte
J. Sabari
Nicolas Girard
Aaron S. Mansfield
K. Park
Caicun Zhou
K. Xia
Atanu Bhattacharya
Mark Wade
Mahadi Baig
Tanu Agrawal
Parthiv J. Mahadevia
Roland Knoblauch
Rachel E. Sanborn
Affiliated Authors:
Catherine A. Shu
Subjects:
Advancements in Lung Cancer Research (OpenAlex Topic)
Positron Emission Tomography Imaging in Oncology (OpenAlex Topic)
Development and Applications of Radiopharmaceuticals (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.esmoop.2024.102581
DOI:
10.1016/j.esmoop.2024.102581
Journal:
ESMO Open
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: